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Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide.
Aberrant expression of miRNAs contributes to HCC development. Here, we observed elevated
miR-520g expression in tumor samples from HCC patients with relapse andmetastasis, and this high
miR-520g expression was correlated with poor survival. Through gain- and loss-of-function studies,
miR-520g was demonstrated to facilitate HCC cell migration, invasion and epithelial–mesenchymal
transition (EMT). SMAD7 was identiﬁed as a direct target of miR-520g. Accordingly, we conclude that
high miR-520g expression promotes HCC cell mobility and EMT by targeting SMAD7, and this is
correlated with reduced survival in HCC patients.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are an abundant group of endogenous
non-coding single strand RNAs of 22 nucleotides [1]. They regu-
late gene expression at post-transcriptional level by translational
repression or degradation of target mRNA. In this manner, they
participate in various biological process including cell develop-
ment [2,3], cell cycle [4], and stem cell renewal [5]. Aberrant
expression of miRNAs plays a key role in cancer development
and progression through modulating oncogenic and tumor sup-
pressor pathways. Using microarray or real-time polymerase chain
reaction (PCR), miRNA expressing proﬁles which can differentiate
cancer and normal tissues have been identiﬁed [6]. Moreover, dif-
ferent types of cancers have varied expression pattern of miRNAs.Due to its high stability in serum, miRNAs are becoming promising
diagnostic and prognostic biomarkers for patients with malignancy
[7,8].
MiR-520g has been proposed as a novel tumor-related miRNA
and has been found to be signiﬁcantly deregulated in tumors.
Up-regulated miR-520g in estrogen receptor (ER) and progesterone
receptor (PR)-negative tumors indicated that it was a maker for
poorer prognosis breast cancer and an attractive target for
therapeutic intervention [9]. Furthermore, miR-520g has been
considered as an oncogene in glioma, medulloblastoma and other
neuroectodermal tumors [10,11]. Recently, the deregulated miR-
NAs in hepatitis B virus-associated hepatocellular carcinoma
(HCC) were identiﬁed by Wang et al. [12,13]. They found that the
expression of miR-520g was upregulated in HCC tissues as com-
pared with that in adjacent non-tumor tissues. Notably, Zhou
et al. reported that the expression of miR-520g was signiﬁcantly
higher in a highly invasive HCC cell line HCCLM3 than that in a
low metastatic HCC cell line MHCC97L [14]. Thus, these promoted
us to investigate the clinical signiﬁcance of miR-520g in HCC and
its role in cell migration and invasion.
In this study, we demonstrate that up-regulation of miR-520g is
observed in the aggressive and metastatic phenotype of HCC. Its
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short survival of HCC patients. In vitro studies demonstrated that
miR-520g facilitated HCC cell migration, invasion and epithelial-
mesenchymal transition (EMT). Furthermore, SMAD family
member 7 (SMAD7) was identiﬁed as a direct target of miR-520g.
Mechanistically, our results demonstrate that miR-520g potenti-
ates the invasive behavior of HCC cells and contributes to tumor
metastasis by inhibiting SMAD7 and promoting EMT.
2. Materials and methods
2.1. Clinical samples
130 HCC samples were collected from patients including 98
males and 32 females, who underwent the resection of their
primary HCC in the Department of Hepatobiliary Surgery at the
Nanfang Hospital of Southern Medical University during January
2006 to December 2008. The clinicopathological data are shown
in Table 1. All samples were used after obtaining informed consent.
Patients did not receive preoperative chemotherapy or emboliza-
tion. In these cases, 34 patients had intrahepatic spreading, venous
inﬁltration or tumor invasion into bile ducts, and 66 patients had
tumor recurrence.
2.2. Real time quantitative reverse transcription-PCR (qRT-PCR)
The PCR ampliﬁcation for the quantiﬁcation of the miR-520g
and U6 was performed using TaqManmiRNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) and TaqMan Human
MiRNA Assay Kit (Applied Biosystems, Foster City, CA, USA). The
relative expression of miR-520g was shown as fold difference
relative to U6.
Primer pairs against Homo sapiens gene SMAD7 (HP208950)
and GAPDH (HP205798) were purchased from OriGene (Beijing,
China). The PCR ampliﬁcation for the quantiﬁcation of the SMAD7
and GAPDH mRNAs was performed using an ABI PRISM 7300
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA) and a SYBR Premix Ex Taq™ ii (Perfect Real Time) Kit
(Takara Bio, Shiga, Japan), as previous reported [15].Table 1
Correlation between the clinicopathologic characteristics and miR-520g expression in
HCC.
Characteristics Total No. of
patients,
n = 130
No. of patients P
miR-
520ghigh
miR-
520glow
Age (y) <50 54 29 25 0.477
P50 76 36 40
Sex Male 98 53 45 0.103
Female 32 12 20
HBV Absent 42 20 22 0.708
Present 88 45 43
Serum AFP level
(ng/ml)
<400 48 19 29 0.069
P400 82 46 36
Tumor size (cm) <5 49 21 28 0.205
P5 81 44 37
No. of tumor
nodules
1 102 47 55 0.088
P2 28 18 10
Cirrhosis Absent 54 25 29 0.477
Present 76 40 36
Venous
inﬁltration
Absent 96 41 55 0.005*
Present 34 24 10
Edmondson-
Steiner grading
I + II 98 43 55 0.015*
III + IV 32 22 10
TNM tumor stage I + II 97 40 57 0.001*
III + IV 33 25 8
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein;
TNM, tumor-node-metastasis.
* Statistically signiﬁcant.2.3. Cell lines and transfection
The human immortalized normal hepatocyte cell line, LO2, and
six HCC cell lines, HepG2, MHCC97L, Hep3B, Huh7, MHCC97H and
HCCLM3 (the Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences, Shanghai, China), were cultured in complete
Dulbecco’s modiﬁed Eagle medium (DMEM, Gibco, Grand Island,
NY, USA) containing 10% fetal bovine serum (FBS, Gibco, Grand
Island, NY, USA) with 100 units/ml penicillin and 100 lg/ml strep-
tomycin (Sigma, St-Louis, MO, USA) in a humidiﬁed containing of
5% CO2 incubator at 37 C.
MiRNA vectors, including miR-520g expression vector
(HmiR0334-MR04), the control vector for miR-520g (CmiR0001-
MR04), miR-520g inhibitor (HmiR-AN0603-AM04) and the nega-
tive control for the miR-520g inhibitor (CmiR-AN0001-AM04),
were purchased from Genecopoeia (Guangzhou, China). Plasmids
carrying wt SMAD7 (pCMV5-SMAD7) were obtained from Addgene
(Cambridge, MA, USA). The targeted sequences for SMAD7 siRNA
duplex (50-AA GCU CAA UUC GGA CAA CAA G-30) or a non-speciﬁc
duplex oligonucleotide as a negative control were synthesized by
Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). Cells were
transfected with the vectors mentioned above using Lipofectamine
2000 according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA).
2.4. Boyden chamber and Transwell assays
A Boyden chamber assay (NeuroProbe, Gaithersburg, MD, USA)
was used to analyze HCC cell migration as previously described
[16]. Transwell assays were done in 6 well plates with Transwell
inserts equipped with 8-lm pores (Nalge Nunc International Corp,
Naperville, IL, USA) coated with matrigel at 1:6 dilution (Becton
Dickinson Labware, Bedford, MA, USA) as previously described
[17].
2.5. Western blot
The following primary antibodies were used in the immuno-
blotting assays: SMAD7 (H-79, sc-11392, Santa Cruz, CA, USA),
E-cadherin (24E10, #3195, Cell Signaling Technology, Danvers,
MA, USA), vimentin (R28, #3932, Cell Signaling Technology, Dan-
vers, MA, USA) and GAPDH (G8140; US Biological, Swampscott,
MA, USA). Horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit secondary antibodies (Bio-Rad, Hercules, CA, USA) were
used at a 1:1000–1:5000 dilution and detected using a Western
Blotting Luminol Reagent (sc-2048; Santa Cruz, CA, USA), as
described in our previous study [15].
2.6. Immunohistochemical staining
Immunohistochemistry was performed on paraformaldehyde-
ﬁxed parafﬁn sections. SMAD7 (H-79, sc-11392, Santa Cruz, CA,
USA) antibody was used in immunohistochemistry with streptavi-
din peroxidase conjugated (SP-IHC) method. Immunohistochemis-
try was performed as previous reported [15]. The percentage of
positive tumor cells was graded as per the following criteria: 0, less
than 10%; 1, 10–30%; 2, 31–50%; 3, more than 50%.
2.7. Luciferase reporter assay
The 30-untranslated region (UTR) sequence of SMAD7 predicted
to interact with miR-520g or a mutated sequence within the pre-
dicted target sites was synthesized and inserted into the XbaI
and FseI sites of the pGL3 control vector (Promega, Madison, WI,
USA). These constructs were named as wt SMAD7-30UTR or mt
SMAD7-30UTR, respectively. For the reporter assay, HepG2 cells
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constructs and miR-520g expression vector, miR-520g inhibitor,
control vector or negative control. After 48 h, the cells were har-
vested and Renilla luciferase activity was measured using the
dual-luciferase reporter assay system (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Results were
obtained from three independent experiments performed in
duplicate.
2.8. Statistical analysis
Results are expressed as mean ± S.E.M. Signiﬁcance was estab-
lished, with the SPSS statistical package for Windows Version 13
(SPSS, Chicago, IL, USA) and GraphPad Prism 5 software (GraphPad
Software, Inc, San Diego, CA, USA), using a Pearson chi-squared
test, a Spearman’s rank correlation coefﬁcient, a two-tailed Stu-
dent’s t test, a Kaplan–Meier plot, a log-rank test or an ANOVA
when appropriate. Difference were considered signiﬁcant when
P < 0.05.
3. Results
3.1. Up-regulation of miR-520g is associated with metastasis and
recurrence of HCC
We tested the expression of miR-520g by qRT-PCR and normal-
ized against an endogenous control (U6 RNA) in 40 pairs of tumor
tissues and matched adjacent non-tumor tissues from HCC
patients who received liver resection. The expression level of
miR-520g in HCC tissues was signiﬁcantly higher than that in
matched adjacent non-tumor liver tissues (P < 0.05, Fig. 1A). HCC
cases that showed intrahepatic spreading, venous inﬁltration or
tumor invasion into bile ducts were considered as aggressive
HCC tissues. As compared with non-aggressive HCC tissues,
miR-520g levels were prominently up-regulated in aggressive
HCC tissues (P < 0.05, Fig. 1B). Furthermore, miR-520g levels were
obviously increased in tumor tissues arising from patients withFig. 1. The expression levels of miR-520g in HCC tissues and cells. Comparing differenc
tissues, (B) aggressive and non-aggressive tumor tissues, (C) HCC tissues arising from re
potentials and the immortalized hepatic cell line LO2. ⁄P < 0.05.intrahepatic tumor recurrence or extrahepatic metastasis as com-
pared with those in tumor tissues arising from patients without
tumor recurrence (P < 0.05, Fig. 1C). Thus, up-regulation of miR-
520g level was correlated with metastasis and recurrence of HCC.
Next, we analyzed miR-520g expression in a non-transformed
hepatic cell line (LO2) and a panel of HCC cell lines (HepG2,
MHCC97L, Huh7, Hep3B, MHCC97H and HCCLM3). The miR-520g
expression was signiﬁcantly up-regulated in all HCC cell lines as
compared with that in LO2 (P < 0.05, Fig. 1D). Moreover, miR-
520g expression in the highly metastatic HCC cell lines, MHCC97H
and HCCLM3, were obviously higher than those in the low meta-
static HCC cell lines including HepG2, MHCC97L, Huh7 and Hep3B
(P < 0.05, Fig. 1D). These data indicates that elevated miR-520g
expression confers increased metastatic potential of HCC cells.
3.2. Clinical signiﬁcance of miR-520g expression in HCC cases
130 samples of HCC specimens were subjected to qRT-PCR for
miR-520g expression. The expression of miR-520g was considered
as either low (n = 65) or high (n = 65) according to the cutoff value,
which was deﬁned as the median of the cohort. As shown in
Table 1, miR-520g was expressed at prominently higher levels in
HCC patients with venous inﬁltration (P = 0.005), high Edmond-
son-Steiner grading (P = 0.015) and advanced TNM tumor stage
(P = 0.001). Furthermore, 130 HCC patients with clinical survival
information (with a median follow-up time of 37.5 months) were
analyzed by Kaplan Meier estimation. Tumors with high expres-
sion of miR-520g indeed associated with worse overall survival
and disease-free survival of HCC patients (P < 0.001, respectively,
Fig. 2). These data indicate that miR-520g may act as a potent bio-
marker for predicting prognosis of HCC patients.
3.3. MiR-520g is correlated with EMT phenotype and invasion ability
in HCC cells
We transduced HCC cell line, HCCLM3, with miR-520g inhibitor
(anti-miR-520g) or negative control (NC). As measured byes in the expression levels of miR-520g between (A) HCC and matched non-tumor
current and non-recurrent groups, and (D) HCC cell lines with different metastatic
Fig. 2. Prognostic signiﬁcance of miR-520g in HCC cases. According to the level of miR-520g expression, Kaplan-Meier 5-year overall and disease-free survival curves of HCC
patients showed that high expression of miR-520g was correlated with poor prognosis. The median expression value obtained for miR-520g of the 130 HCC samples detected
by qRT-PCR was chosen as the cutoff value.
Fig. 3. MiR-520g regulates EMT phenotype and HCC cell mobility. (A) Cell migration and invasion as measured by Boyden chamber and Transwell assays were inhibited by
down-regulation of miR-520g in HCCLM3 cells as compared with control cells. n = 3 repeats with similar results; ⁄P < 0.05. (B) miR-520g overexpressing HepG2 cells conferred
a higher number of migrated and invaded cells as compared with control cells. n = 3 repeats with similar results; ⁄P < 0.05. (C) Representative Western blot analysis of E-
cadherin and vimentin in HCCLM3 cells with miR-520g inhibitor transfection and HepG2 cells with miR-520g transfection was shown. n = 6; ⁄P < 0.05.
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regulated by miR-520g inhibitor in HCCLM3 cells (P < 0.05, data
not shown). Boyden chamber assays were performed to test the
effect of altering miR-520g levels on HCC cell migration. We found
that down-regulation of miR-520g led to a signiﬁcant reduction of
cell migration in HCCLM3 cells (P < 0.05, Fig. 3A). Furthermore, as
determined by Transwell assays, the number of invaded HCCLM3cells was signiﬁcantly reduced after reduction of miR-520g
(P < 0.05, Fig. 3A). Next, miR-520g overexpressing HepG2 cells
was established and conﬁrmed by qRT-PCR (P < 0.05, data not
shown). As expected, up-regulation of miR-520g obviously pro-
moted HCC cell migration and invasion (P < 0.05, respectively,
Fig. 3B). Furthermore, suppression of EMT in HCCLM3 cells with
down-regulation of miR-520g was associated with elevated
106 H. Kan et al. / FEBS Letters 589 (2015) 102–109expression of E-cadherin and reduced expression of vimentin
(Fig. 3C). Otherwise, up-regulation of miR-520g-induced EMT
was associated with reduced expression of E-cadherin and elevated
expression of vimentin in HepG2 cells. These data indicate that
miR-520g is associated with EMT phenotype and cell mobility in
HCC cell lines.
3.4. SMAD7 is identiﬁed as a functional target of miR-520g and is
down-regulated in HCC specimens
To disclose the molecular mechanisms by which miR-520g
induces EMT in HCC, predicted target genes of miR-520g were
retrieved and analyzed using publicly available databases (Target-
Scan 6.2 and MiRanDa). Among these, EMT-associated genes were
selected for further investigating. Signiﬁcantly, SMAD7, which is
known to inhibit EMT and tumor metastasis by blocking TGFb sig-
naling [18,19], was predicted as one of the targets of miR-520g.
HepG2 cells that were transfected with miR-520g and control vec-
tors were subjected to qRT-PCR and Western blot for SMAD7
expression. Both SMAD7 mRNA and protein levels were signiﬁ-
cantly reduced by up-regulation of miR-520g in HepG2 cells
(P < 0.05, respectively, Fig. 4A and B). To further demonstrate that
SMAD7 is directly targeted by miR-520g in HCC cells, we investi-
gated whether the miR-520g directly interacted with the 30-UTR
of SMAD7 mRNA using a dual-luciferase reporter assay. As
expected, miR-520g signiﬁcantly inhibited the luciferase activity
of SMAD7 containing a wild-type (wt) 30-UTR but did not suppress
activity of SMAD7 with a mutant (mt) 30-UTR (P < 0.05, Fig. 4C and
D). When anti-miR-520g was transfected, an increase in luciferase
activity of wt SMAD7 30-UTR was observed. However, with the mt
SMAD7 30-UTR constructs, there was no relative increase in activity
(P < 0.05, Fig. 4C and D). Thus, our data strongly suggest that
SMAD7 is a target of miR-520g in HCC.
Expression of SMAD7 was further detected by qRT-PCR and
immunohistochemistry in the previous cohort of 40 pairs of HCC
and normal tumor-adjacent tissues. Both SMAD7 mRNA and pro-
tein levels were demonstrated to be signiﬁcantly lower in HCC tis-
sues as compared with those in non-cancerous tissues (P < 0.05,Fig. 4. SMAD7 is identiﬁed as a functional target of miR-520g in HCC. (A) qRT-PCR and
control vectors transfection. n = 6; ⁄P < 0.05. (C) miR-520g and its putative binding sequen
complementary site for the seed region of miR-520g (wt, wild type; mt, mutant type). (D)
30-UTR of SMAD7. Anti-miR-520g led to a noticeable increase in luciferase activity of wrespectively, Fig. 5A and B). 130 samples of HCC tissues were sub-
jected to immunostaining for SMAD7 expression. SMAD7 immuno-
reactivity was considered as either negative (score 0) or positive
(scores 1-3). In these cases, SMAD7 expression was detected in
46.2% (30/65) of the HCC samples with low expression of miR-
520g, whereas only 20.0% (13/65) of the HCC specimens with high
expression of miR-520g showed a positive SMAD7 signal (P < 0.05,
Fig. 5C). Furthermore, Spearman correlation analysis indicated that
miR-520g was inversely correlated with SMAD7 expression in HCC
tissues (r = 0.7362, P < 0.001).
3.5. MiR-520g promotes EMT and HCC cell mobility by targeting
SMAD7
To further conﬁrm the role of SMAD7 in miR-520g-mediated
EMT and cell mobility in HCC cells, we restored the expression of
SMAD7 in miR-520g overexpressing HepG2 cells by transfecting
pCMV5-SMAD7 plasmids. As conﬁrmed by immunoblotting, resto-
ration of SMAD7 suppressed EMT in miR-520g overexpressing
HepG2 cells and was correlated with up-regulation of epithelial
biomarker, Ecadherin, and reduced expression of mesenchymal
biomarker, vimentin (P < 0.05, respectively, Fig. 6A). Furthermore,
the migration and invasion abilities of miR-520g overexpressing
HepG2 cells was partially abolished after pCMV5-SMAD7 transfec-
tion (P < 0.05, respectively, Fig. 6B), which was consistent with
above results. Similarly, SMAD7 knockdown promoted the migra-
tion and invasion of miR-520g downregulating HCCLM3 cells
(P < 0.05, respectively, Fig. 6C). All the data indicate that miR-
520g promotes EMT and cell mobility by targeting SMAD7 in
HCC cells.
4. Discussion
Increasing evidences have demonstrated that the deregulation
and dysfunction of miRNAs play a critical role in the initiation
and progression of HCC [20]. However, miRNAs that are involved
in the recurrence and metastasis of HCC remain poorly investi-
gated. In this study, we initially detected the expression level of(B) Western blot analysis of SMAD7 expression in HepG2 cells with miR-520g or
ce in the 30-UTR of SMAD7. The mutant miR-520g binding site was generated in the
MiR-520g signiﬁcantly suppressed the luciferase activity that carried wt but not mt
t 30-UTR of SMAD7. n = 3 repeats with similar results; ⁄P < 0.05.
Fig. 5. An inverse correlation between miR-520g and SMAD7 expression is observed in HCC. Comparing differences in the expression levels of SMAD7 (A) mRNA and (B)
protein between HCC and matched non-tumor tissues. ⁄P < 0.05. (C) Representative immunostaining showed negative expression of SMAD7 in miR-520 high-expressing HCC
tissue and positive expression of SMAD7 in miR-520 low-expressing tumor. A signiﬁcant inverse correlation between miR-520g and SMAD7 expression was observed in HCC
tissues. Scale bar: 100 lm; ⁄P < 0.05.
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adjacent tissues. Our data indicated that the expression of miR-
520g in HCC tissues was obviously higher than that in non-tumor
tissues. Moreover, miR-520g was expressed at prominent higher
levels in aggressive tumor tissues as compared with that in non-
aggressive tumor tissues. Importantly, our results showed that
high expression of miR-520g conferred a signiﬁcant higher recur-
rence rate for HCC patients. Clinical analysis found that high
expression of miR-520g was signiﬁcantly correlated with venous
inﬁltration, high Edmondson-Steiner grading and advanced TNM
tumor stage in HCC. Kaplan–Meier’s plots demonstrated that high
expression of miR-520g was signiﬁcantly associated with poor sur-
vival of HCC patients. Furthermore, HCC cell lines, especially high
metastatic cell lines (MHCC97H and HCCLM3), showed obviously
higher levels of miR-520g as compared with the non-transformed
hepatic cell line LO2. Altogether, these results suggest that miR-
520g is critical for prognosis determination in HCC patients.
Next, we further investigated the role of miR-520g in HCC cells.
Boyden chamber and Transwell assays were performed to test HCC
cell migration and invasion abilities. We found that down-
regulation of miR-520g inhibited cell migration and invasion in
HCCLM3 cells. And up-regulation of miR-520g increased the num-
ber of migrated and invaded HepG2 cells. These data suggest that
miR-520g indeed promotes HCC cell migration and invasion.
EMT, a dynamic and reversible cellular process, is characterized
by loss of cell polarity and intracellular junctions and acquirementof mesenchymal features, resulting in increased HCC cell migration
and invasion [21]. Thus, we determined the expression of epithelial
marker, E-cadherin, and mesenchymal marker, vimentin in HCC
cells with altering expression of miR520g. Interestingly, we dem-
onstrated that down-regulation of miR-520g inhibited EMT and
was associated with elevated expression of E-cadherin and reduced
expression of vimentin in HCCLM3 cells. Meanwhile, up-regulation
of miR-520g promoted EMT and was associated with reduced
expression of E-cadherin and elevated expression of vimentin.
Taken together, miR-520g may promote HCC cell migration and
invasion by inducing EMT.
Predicted target genes of miR-520g were retrieved and analyzed
using publicly available databases (TargetScan and Miranda). The
putative binding sequences of miR-520g were found in the
30-UTR of SMAD7. SMAD7 is a member of the SMAD family of
proteins, which belong to the transforming growth factor (TGF)-b
super family of ligands [18]. SMAD7 is involved in cell signaling
and is a TGFb receptor I (TGFbRI) antagonist that blocks TGFb1
[22,23]. Smith et at found that miR-106b-25 cluster activated
TGF-b signaling pathway through down-regulation of SMAD7 to
induce EMT and tumor-initiating cell characteristics in human
breast cancer [19]. Notably, recent study reported that miR-216a/
217 induced EMT by activating the TGF-b signaling pathway by
targeting SMAD7 in HCC [18]. We investigated the regulatory effect
of miR-520g on SMAD7 in HCC cells. Our data indicated that
up-regulation of miR-520g reduced the expression levels of SMAD7
Fig. 6. MiR-520g induces HCC cell migration, invasion and EMT by targeting SMAD7. (A) Western blot analysis of the expression of E-cadherin and vimentin in pCMV5-
SMAD7 transfected miR-520g overexpressing HepG2 cells. n = 6; ⁄P < 0.05. (B) Migration and invasion abilities of the stable transfected cells following restoration of SMAD7 in
miR-520g overexpressing HepG2 cells were analyzed by Boyden chamber and Transwell assays. n = 3 repeats with similar results; ⁄P < 0.05. (C) SMAD7 knockdown by a
speciﬁc siRNA promoted the migration and invasion of miR-520g downregulating HCCLM3 cells. n = 3 repeats with similar results; ⁄P < 0.05.
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a direct functional target of miR-520g in HCC. Furthermore, expres-
sion of SMAD7 in HCC tissues was obviously lower as compared
with that in matched normal non-tumor tissues, which was consis-
tent with previous studies [18]. Otherwise, a signiﬁcant inverse
correlation between miR-520g and SMAD7 expression was
observed in HCC tissues. Importantly, the regulatory effects of
altered expression of miR-520g on EMT and cell mobility were par-
tially abolished by SMAD7 in HCC cells. Accordingly, we suggest
that miR-520g promotes EMT and cell mobility by targeting
SMDA7 in HCC. In the previous paper, miR-520c expression
reduced cell invasiveness and had a tumour suppressive role in
breast cancer, and that this was attributed to both the NF-jB and
TGF-b/Smad2/3 pathways [24]. MiR-520c has the same seed region
as miR-520g and yet high expression appears to result in reduced
invasiveness in breast cancer. Interestingly, Toffanin et al. reported
that the expression of miR-520c increased proliferation, migration,
and invasion of HCC cells in vitro [25]. Therefore, the functional
signiﬁcance of miRNAs in cancer development and progression
seem to be cancer-type speciﬁc.
In conclusion, we ﬁnd that miR-520g is up-regulated in HCC and
its high expression is related to poor prognostic features. More-
over, high expression of miR-520g is a prognostic marker forpredicting poor survival of HCC patients. In vitro studies demon-
strate that miR-520g induces HCC cell migration, invasion and
EMT. Mechanistically, we suggest that miR-520g promotes EMT
and HCC cell mobility by suppressing SMAD7. Taken together, we
consider that miR-520g may potentially act as a clinical biomarker,
and may also be a therapeutic target, in HCC.
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